All In Biotech

Drug Trial Radar · NCT07081646

A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.

A Phase 1b/2 Study of AZD0120 (Also Known as GC012F), a Chimeric Antigen Receptor T Cell Therapy Targeting CD19 and B Cell Maturation Antigen in Participants With Relapsed or Refractory AL Amyloidosis.

Last checked: Nov 19, 2026Latest source record: Jul 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

91

Planned (sponsor's estimate)

Start

Aug 18, 2025

Primary completion

Aug 15, 2029

Study completion Feb 14, 2031

Sponsor

Lead sponsor
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
Sponsor type
Industry
First posted
Jul 23, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Open-label Phase 1b/2 study with primary objective of this study is to evaluate the safety, tolerability and efficacy of AZD0120 in participants with light chain (AL) amyloidosis.

Conditions

  • Relapsed AL Amyloidosis
  • Refractory AL Amyloidosis
  • Light Chain Amyloidosis
  • Amyloidosis

Interventions

  • AZD0120Drug

    Participants will receive AZD0120 via intravenous (IV) infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1b: Number of Participants With incidence and severity of Treatment-emergent Adverse EventsTime frame: Through study completion, a minimum of 6 months
  2. Phase 2: Proportion of Participants Achieving Complete ResponseTime frame: Through study completion, a minimum of 6 months

Locations

18 sites in 3 countries. Site status is shown where the registry gives one.

  • Research Site

    Phoenix, Arizona · Recruiting

  • Research Site

    San Francisco, California · Recruiting

  • Research Site

    Tampa, Florida · Recruiting

  • Research Site

    Boston, Massachusetts · Recruiting

  • Research Site

    Detroit, Michigan · Recruiting

  • Research Site

    Rochester, Minnesota · Recruiting

  • Research Site

    St Louis, Missouri · Recruiting

  • Research Site

    New York, New York · Recruiting

  • Research Site

    New York, New York · Recruiting

  • Research Site

    New York, New York · Recruiting

  • Research Site

    Cleveland, Ohio · Recruiting

  • Research Site

    Nashville, Tennessee · Recruiting

  • Research Site

    Calgary, Alberta, Canada · Withdrawn

  • Research Site

    Calgary, Alberta, Canada · Recruiting

  • Research Site

    Toronto, Ontario, Canada · Withdrawn

  • Research Site

    Toronto, Ontario, Canada · Recruiting

  • Research Site

    London, United Kingdom · Withdrawn

  • Research Site

    London, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.